SGX, Boehringer, Sense Proteomic, Procognia, MDS Proteomics, Lilly, OGS, Wyeth, Fox Foundation, U. Penn, Biosentients, iSentient, NanoInk | GenomeWeb

SGX Gets Boehringer Ingelheim Deal

Structural Genomix of San Diego, Calif., and Boehringer Ingelheim Pharmaceuticals said last week they started a two-year collaboration. Under the agreement, SGX will solve the three dimensional structures of protein targets provided by Boehringer. Subsequently, SGX will generate co-crystals with potential drug lead compounds.

Boehringer hopes that SGX's high-throughput protein structure determination platform will help it optimize lead compounds and improve drug candidates.


Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.